Table 1 Clinical Characteristics of the study cohort in fetuses with RAA
Clinical characteristics | Total | RAA subtypes | RAA subgroups | ||||
|---|---|---|---|---|---|---|---|
MI n/N, (%) | ALSA n/N, (%) | p value | Isolated RAA n/N, (%) | Non-isolated RAA n/N, (%) | p value | ||
Gestational weeks(weeks) | 25+6 (24+3, 28+0) | 25+1 (23+2, 27+3) | 25+3 (24+2, 28+5) | 0.535 | 25+6 (24+3, 28+4) | 25+3 (24+2, 27+1) | 0.117 |
Maternal age (years) | 29.8 ± 4.4 | 30.6 ± 5.5 | 30.2 ± 4.7 | 0.797 | 29.9 ± 4.5 | 29.8 ± 4.4 | 0.895 |
Advanced maternal age | 27/153 (17.6%) | 2/8 (25%) | 13/54 (24.1%) | 1.000 | 18/99 (18.2%) | 9/54 (16.7%) | 0.814 |
Primiparas | 49/153 (32.0%) | 3/8 (37.5%) | 17/54 (31.5%) | 1.000 | 30/99 (30.3%) | 19/54 (35.2%) | 0.536 |
Other sonographic anomalies | 54/153 (35.3%) | 6/8 (75%) | 15/54 (27.8%) | 0.026 | – | – | – |
ICA | 25/153 (16.3%) | 5/8 (62.5%) | 4/54 (7.4%) | 0.000 | – | – | – |
ECA | 15/153 (9.8%) | 1/8 (12.5%) | 7/54 (13.0%) | 1.000 | – | – | – |
ICA+ECA | 14/153 (9.2%) | 0/8 (0) | 4/54 (7.4%) | 0.567 | – | – | – |
Detected chromosomal abnormalities | |||||||
(Likely) pCNVs | 14/153 (9.2%) | 1/8 (12.5%) | 7/54 (13.0%) | 1.000 | 5/99 (5.1%) | 9/54 (16.7%) | 0.037 |
VOUS | 9/153 (5.9%) | 1/8 (12.5%) | 3/54 (5.6%) | 0.433 | 5/99 (5.1%) | 4/54 (7.4%) | 0.816 |
Monogenic variants | 1/5 (20%) | 0/1 (0) | 0/1 (0) | – | 0/1 (0) | 1/4 (25%) | 1.000 |
Pregnancy outcomes | |||||||
Livebirth | 99/153 (64.7%) | 6/8 (75%) | 37/54 (68.5%) | 1.000 | 73/99 (73.7%) | 26/54 (48.1%) | 0.002 |
premature birth | 7/153 (4.6%) | 1/8 (12.5%) | 3/54 (5.6%) | 0.433 | 1/99 (1.0%) | 6/54 (11.1%) | 0.008 |
Full-term delivery | 92/153 (60.1%) | 5/8 (62.5%) | 34/54 (63.0%) | 1.000 | 72/99 (72.7%) | 20/54 (37.0%) | 0.000 |
Termination of pregnancy | 22/153 (14.4%) | 1/8 (12.5%) | 7/54 (13.0%) | 1.000 | 2/99 (2.0%) | 20/54 (37.0%) | 0.000 |
Lost to follow-up | 32/153 (20.9%) | 1/8 (12.5%) | 10/54 (18.5%) | 1.000 | 24/99 (24.2%) | 8/54 (14.8%) | 0.171 |